Matching slides 303,780
Current window 201,511-201,540
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all

Component

201,511-201,540 of 303,780

filter-aware
02
9 Meters Biopharma | Investor Presentation Deck | 30 slides9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations 1 hit
03
The slide uses a stepped process diagram to link scientific focus to business outcomes.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
04
9 Meters Biopharma | Investor Presentation Deck | 30 slides9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
05
The slide uses a visual connection (lines) to link each executive to a set of company logos representing their past experience.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations 1 hit
07
The slide uses a Gantt-style visualization to represent clinical trial progress.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations 1 hit
08
9 Meters Biopharma | Investor Presentation Deck | 30 slides9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations 1 hit
09
9 Meters Biopharma | Investor Presentation Deck | 30 slides9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations Beat · Solution1 hit
10
Includes anatomical comparison of normal vs. SBS GI tract.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
11
The slide uses a medical illustration to show the digestive tract and the specific portion of the ileum removed in SBS patients.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
12
Uses a path-based diagram to illustrate the progression from diagnosis to long-term outcomes and patient experience.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations Beat · Solution1 hit
13
The slide uses a biological process diagram to illustrate the therapeutic mechanism.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations Beat · Solution1 hit
14
Uses a pyramid diagram to illustrate the patient population spectrum for SBS.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations 1 hit
15
The text 'Vurolenatide for short Bowel syndrome Regardless of pArental support requiremeNT' uses an acrostic-like emphasis on letters to spell VIBRANT.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations 1 hit
16
The title uses an acrostic-style emphasis on letters (V, B, R, A, N) which spells VBRAN, likely a branding or mnemonic device.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations 1 hit
17
The slide details a 4-group study design with varying dosages of medication vs placebo over a 28-day treatment period.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations 1 hit
18
The table displays N, sex, age, weight, race, ethnicity, and surgical status for placebo and three treatment arms.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations 1 hit
19
The chart compares placebo, 50 mg Q2W, 50 mg weekly, and 100 mg Q2W groups, highlighting percentage decreases relative to the placebo increase.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations Beat · Traction1 hit
22
The slide highlights the efficacy of the 50 mg Q2W dose compared to other cohorts.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations Beat · Traction1 hit
23
TSO likely refers to a specific clinical biomarker or symptom score.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations Beat · Traction1 hit
24
The chart illustrates the 'stacking effect' (undesirable accumulation) in the 50 mg weekly and 100 mg Q2W groups, contrasting them with the 50 mg Q2W group which stays within the target range.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations 1 hit
27
The slide uses checkmarks to denote key achievements/findings.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations 1 hit
28
9 Meters Biopharma | Investor Presentation Deck | 30 slides9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations Beat · Next Steps1 hit
29
9 Meters Biopharma | Investor Presentation Deck | 30 slides9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations Beat · Next Steps1 hit
02
ads-tec Energy | Investor Presentation Deck | 32 slidesads-tec Energy | Investor Presentation Deck | 32 slides · ads-tec Energy
Conference presentation Investor relations Beat · Humble Origins1 hit
03
ads-tec Energy | Investor Presentation Deck | 32 slidesads-tec Energy | Investor Presentation Deck | 32 slides · ads-tec Energy
Conference presentation Investor relations Beat · Humble Origins1 hit
08
Values are in kEUR.ads-tec Energy | Investor Presentation Deck | 32 slides · ads-tec Energy
Conference presentation Investor relations Beat · Early StrugglesLoop · Before After1 hit
32
Zegna | Results Presentation Deck | 39 slidesZegna | Results Presentation Deck | 39 slides · Ermenegildo Zegna Group
Conference presentation Investor relations 1 hit
33
Includes detailed footnotes explaining specific adjustments made to arrive at Adjusted EBIT.Zegna | Results Presentation Deck | 39 slides · Ermenegildo Zegna Group
Conference presentation Investor relations 1 hit
38
Zegna | Results Presentation Deck | 39 slidesZegna | Results Presentation Deck | 39 slides · Ermenegildo Zegna Group
Conference presentation Investor relations 1 hit
39
Zegna | Results Presentation Deck | 39 slidesZegna | Results Presentation Deck | 39 slides · Ermenegildo Zegna Group
Conference presentation Investor relations 1 hit